Completed

AI-Human Collaboration in Liver Tumor Diagnosis with DCE-CT

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to evaluate how artificial intelligence can assist doctors in diagnosing liver tumors using dynamic contrast-enhanced computed tomography in patients.

What is being tested

AI-human collaboration for CE-CTs diagnosis

Diagnostic Test
Who is being recruted

Adenocarcinoma+13

+ Carcinoma

+ Cysts

Over 18 Years
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: September 2025
See protocol details

Summary

Principal SponsorShengjing Hospital
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 2025

Actual date on which the first participant was enrolled.

This clinical study explores how artificial intelligence (AI) can work together with human doctors to improve the diagnosis of liver tumors using a special type of imaging called dynamic contrast-enhanced computed tomography (DCE-CT). AI has shown great potential in analyzing medical images, sometimes even matching or surpassing the skills of experienced doctors. However, challenges remain in applying these AI tools in real-world settings due to variability in patient populations and imaging conditions. By investigating this collaboration, the study aims to enhance diagnostic accuracy and create a more reliable framework for diagnosing liver tumors. In the study, radiologists and an AI system will simultaneously analyze the same DCE-CT images. Radiologists will follow their usual procedures, while the AI system provides its analysis independently. When their assessments differ, a panel of experts will review the cases to reach a final decision. This process helps to identify how human expertise and AI can complement each other, improving overall diagnostic performance. By including a wide range of clinical cases, the study seeks to ensure the AI’s effectiveness across different scenarios, ultimately aiming to improve the integration of AI into clinical practice.

Official TitleAI-human Collaborative Diagnosis of Liver Tumors Using CE-CT
NCT07153783
Principal SponsorShengjing Hospital
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

10333 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AdenocarcinomaCarcinomaCystsDigestive System DiseasesDigestive System NeoplasmsCarcinoma, HepatocellularLiver DiseasesLiver NeoplasmsNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Glandular and EpithelialPathological Conditions, Signs and SymptomsCholangiocarcinomaFocal Nodular HyperplasiaPathological Conditions, Anatomical

Criteria

Inclusion Criteria: 1. Age range 18 years and above 2. Underwent dynamic contrast-enhanced abdominal CT examination with liver coverage 3. Imaging must include at least three required phases: non-contrast, arterial phase, and venous phase; an delayed phase is optional 4. Complete imaging data that meet AI system analysis requirements. Exclusion Criteria: 1. History of recent upper-abdominal surgery (within 30 days) or major hepatobiliary-pancreatic surgery affecting liver evaluation (e.g., liver transplantation or Whipple procedure); patients with prior simple cholecystectomy or single-lesion interventional procedures are not excluded 2. History of recent hepatic trauma (within 30 days) 3. Poor image quality or severe noise artifacts (e.g., metal or motion artifacts) 4. Missing required imaging phases (required at least non-contrast, arterial, and venous phases) or inadequate scan range (e.g., lower-abdomen CT such as pelvic or rectal scans not covering the liver)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
In the prospective analysis phase, patients undergo routine Multiphasic Contrast-Enhanced Computed Tomography (CE-CT) imaging. The scans are evaluated through two parallel pathways: standard radiologist interpretation (without AI input) and independent AI analysis. When diagnostic discrepancies occur, a senior radiologist or multidisciplinary expert panel reviews the case and provides the definitive diagnosis.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Shengjing Hospital of China Medical University

Shenyang, ChinaOpen Shengjing Hospital of China Medical University in Google Maps
CompletedOne Study Center